Journal of Business Ethics 85:3 - 23 (2009)
|Abstract||Today there is a growing wave of demands being placed upon the pharmaceutical industry to contribute to improved access to medicines for poor patients in the developing countries. 1 This article aims to contribute to the development of a systematic approach and broad consensus about shared benchmarks for good corporate practices in this area. A consensus corridor on what constitutes an appropriate portfolio of corporate responsibilities for access to medicines -especially under conditions of 'failing states' and 'market failure' 2 – is not only in the interest of the world's poor, but also of corporations that want to contribute to the solution of one of the most significant social problems of our time|
|Keywords||No keywords specified (fix it)|
|Through your library||Configure|
Similar books and articles
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
Debora Diniz (2009). Rationing the Access to High Cost Medicines in Developing Countries. Developing World Bioethics 9 (2):ii-iii.
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
Jillian Clare Cohen & Patricia Illingworth (2003). The Dilemma of Intellectual Property Rights for Pharmaceuticals: The Tension Between Ensuring Access of the Poor to Medicines and Committing to International Agreements. Developing World Bioethics 3 (1):27–48.
Richard E. Ashcroft (2005). Access to Essential Medicines: A Hobbesian Social Contract Approach. Developing World Bioethics 5 (2):121–141.
Alejandro Hazera (1995). A Comparison of Japanese and U.S. Corporate Financial Accountability and its Impact on the Responsibilities of Corporate Managers. Business Ethics Quarterly 5 (3):479-497.
Rudolf V. van Puymbroeck (2010). Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: Conversion + Calculation. Journal of Law, Medicine and Ethics 38 (3):520-549.
Klaus M. Leisinger (2005). The Corporate Social Responsibility of The Pharmaceutical Industry. Business Ethics Quarterly 15 (4):577-594.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Added to index2009-01-28
Total downloads18 ( #67,474 of 548,984 )
Recent downloads (6 months)1 ( #63,327 of 548,984 )
How can I increase my downloads?